Two of the most challenging breast cancers to treat are the triple-negative breast cancers (TNBCs) and HER2 breast cancers. These cancer types are aggressive and prone to treatment resistance. There is an urgent need to develop targeted and personalised treatments for these breast cancer subgroups. This grant is fully funding a new study to investigate an innovative protein target treatment, developed by Prof. Daly. Prof. Daly’s team have identified a signalling protein, called TAOK2, which is needed for some TNBC and HER2 cancer cell types to grow and spread. They hypothesise that it may be possible to use this protein as a predictive test for patients, in order to determine which treatment drugs will be most effective for their individual cancer. The potential outcome of this work will be validation of TAOK2 as a target for future drug development, which will lead to novel targeted and personalised treatments for triple-negative and HER2 breast cancers and significantly reduce patient morbidity and mortality.